. Author manuscript; available in PMC: 2017 Oct 12.

Published in final edited form as: J Hum Genet. 2017 Feb 23;62(6):589–597. doi: 10.1038/jhg.2017.19

Table 1.

Summary of pharmacological data for GluN1-G620R

	wild-type GluN1/GluN2A	1-G620R/GluN2A	wild-type GluN1/GluN2B	1-G620R/GluN2B
Glutamate, EC₅₀, μM (n)	4.2 ± 0.48 (16)	7.5 ± 0.40 (13)^a	0.80 ± 0.15 (9)	2.3 ± 0.30 (8)^a
Glycine, EC₅₀, μM (n)	1.0 ± 0.06 (16)	1.9 ± 0.10 (13)^a	0.27 ± 0.04 (6)	0.49 ± 0.02 (5)^a
Mg²⁺, IC₅₀, μM (n)^b	25 ± 2.3 (10)	446 ± 265 (13)^a	22 ± 2.5 (6)	>1000^a
Proton, % (n)^c	47 ± 2.7 (12)	25 ± 1.4 (11)^a	16 ± 1.2 (6)	9.6 ± 0.29 (5)^a
Zinc, IC₅₀, nM (n)	24 ± 2.6 (5)	9.2 ± 0.28 (8)^a	–	–
% inhibition by zinc^d	53 ± 2.3% (5)	77 ± 1.6% (8)^a	–	–

The data are expressed as mean ± s.e.m. (n).

P<0.01, compared to the corresponding wild type, unpaired t-test; agonist potency was compared using logEC₅₀ or logIC₅₀ values.

Holding potential of −60 mV.

Percentage current remaining at pH 6.8 compared with the pH 7.6.

At 300 nM of zinc.

For all comparisons, number of samples was chosen a priori to give power to detect a 40% change of 0.8.